ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA approves third gene therapy for large B-cell lymphoma
February 09, 2021Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials. -
Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma
December 11, 2019Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. -
FDA Approves Second CAR-T Cell Therapy and first for certain types of NHL
October 20, 2017has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
Pharma Sources Insight January 2025
